PMID- 31486447
OWN - NLM
STAT- MEDLINE
DCOM- 20200211
LR  - 20200211
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 10
IP  - 9
DP  - 2019 Sep 1
TI  - The effects of resveratrol on metabolic status in patients with type 2 diabetes 
      mellitus and coronary heart disease.
PG  - 6042-6051
LID - 10.1039/c9fo01075k [doi]
AB  - This study was performed to investigate the effects of resveratrol on metabolic 
      status in patients with type 2 diabetes mellitus (T2DM) and coronary heart 
      disease (CHD). This randomized, double-blind, placebo-controlled trial was 
      performed with 56 patients having T2DM and CHD. The patients were randomly 
      divided into two groups to receive either 500 mg resveratrol per day (n = 28) or 
      placebo (n = 28) for 4 weeks. Resveratrol reduced fasting glucose (beta-10.04 mg 
      dL(-1); 95% CI, -18.23, -1.86; P = 0.01), insulin (beta-1.09 muIU mL(-1); 95% CI, 
      -1.93, -0.24; P = 0.01) and insulin resistance (beta-0.48; 95% CI, -0.76, -0.21; P = 
      0.001) and significantly increased insulin sensitivity (beta 0.006; 95% CI, 0.001, 
      0.01; P = 0.02) when compared with the placebo. Resveratrol also significantly 
      increased HDL-cholesterol levels (beta 3.38 mg dL(-1); 95% CI, 1.72, 5.05; P < 
      0.001) and significantly decreased the total-/HDL-cholesterol ratio (beta-0.36; 95% 
      CI, -0.59, -0.13; P = 0.002) when compared with the placebo. Additionally, 
      resveratrol caused a significant increase in total antioxidant capacity (TAC) (beta 
      58.88 mmol L(-1); 95% CI, 17.33, 100.44; P = 0.006) and a significant reduction 
      in malondialdehyde (MDA) levels (beta-0.21 mumol L(-1); 95% CI, -0.41, -0.005; P = 
      0.04) when compared with the placebo. Resveratrol upregulated PPAR-gamma (P = 0.01) 
      and sirtuin 1 (SIRT1) (P = 0.01) in the peripheral blood mononuclear cells 
      (PBMCs) of T2DM patients with CHD. Resveratrol supplementation did not have any 
      effect on inflammatory markers. Four-week supplementation of resveratrol in 
      patients with T2DM and CHD had beneficial effects on glycemic control, 
      HDL-cholesterol levels, the total-/HDL-cholesterol ratio, TAC and MDA levels. 
      Resveratrol also upregulated PPAR-gamma and SIRT1 in the PBMCs of T2DM patients with 
      CHD.
FAU - Hoseini, Asma
AU  - Hoseini A
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com 
      namazi-gh@kaums.ac.ir.
FAU - Namazi, Gholamreza
AU  - Namazi G
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com 
      namazi-gh@kaums.ac.ir.
FAU - Farrokhian, Alireza
AU  - Farrokhian A
AD  - Department of Cardiology, School of Medicine, Kashan University of Medical 
      Sciences, Kashan, Iran.
FAU - Reiner, Zeljko
AU  - Reiner Z
AD  - Department of Internal Medicine, University Hospital Centre Zagreb, School of 
      Medicine, University of Zagreb, Zagreb, Croatia.
FAU - Aghadavod, Esmat
AU  - Aghadavod E
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com 
      namazi-gh@kaums.ac.ir.
FAU - Bahmani, Fereshteh
AU  - Bahmani F
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com 
      namazi-gh@kaums.ac.ir.
FAU - Asemi, Zatollah
AU  - Asemi Z
AUID- ORCID: 0000-0001-5265-4792
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com 
      namazi-gh@kaums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190905
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Insulin)
RN  - 0 (PPAR gamma)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 3.5.1.- (Sirtuin 1)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/metabolism
MH  - Cholesterol, HDL/metabolism
MH  - Coronary Disease/*drug therapy/genetics/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/genetics/*metabolism
MH  - Dietary Supplements/analysis
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Insulin/metabolism
MH  - Insulin Resistance
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Middle Aged
MH  - PPAR gamma/genetics/metabolism
MH  - Resveratrol/*administration & dosage
MH  - Sirtuin 1/genetics/metabolism
EDAT- 2019/09/06 06:00
MHDA- 2020/02/12 06:00
CRDT- 2019/09/06 06:00
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2020/02/12 06:00 [medline]
PHST- 2019/09/06 06:00 [entrez]
AID - 10.1039/c9fo01075k [doi]
PST - ppublish
SO  - Food Funct. 2019 Sep 1;10(9):6042-6051. doi: 10.1039/c9fo01075k. Epub 2019 Sep 5.